Skip to Content
Merck
  • The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.

The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.

Nature communications (2016-06-30)
Mark R Woodford, Diana M Dunn, Adam R Blanden, Dante Capriotti, David Loiselle, Chrisostomos Prodromou, Barry Panaretou, Philip F Hughes, Aaron Smith, Wendi Ackerman, Timothy A Haystead, Stewart N Loh, Dimitra Bourboulia, Laura S Schmidt, W Marston Linehan, Gennady Bratslavsky, Mehdi Mollapour
ABSTRACT

Heat shock protein-90 (Hsp90) is an essential molecular chaperone in eukaryotes involved in maintaining the stability and activity of numerous signalling proteins, also known as clients. Hsp90 ATPase activity is essential for its chaperone function and it is regulated by co-chaperones. Here we show that the tumour suppressor FLCN is an Hsp90 client protein and its binding partners FNIP1/FNIP2 function as co-chaperones. FNIPs decelerate the chaperone cycle, facilitating FLCN interaction with Hsp90, consequently ensuring FLCN stability. FNIPs compete with the activating co-chaperone Aha1 for binding to Hsp90, thereby providing a reciprocal regulatory mechanism for chaperoning of client proteins. Lastly, downregulation of FNIPs desensitizes cancer cells to Hsp90 inhibitors, whereas FNIPs overexpression in renal tumours compared with adjacent normal tissues correlates with enhanced binding of Hsp90 to its inhibitors. Our findings suggest that FNIPs expression can potentially serve as a predictive indicator of tumour response to Hsp90 inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-CFTR Antibody, clone M3A7, clone M3A7, Upstate®, from mouse